SciELO - Scientific Electronic Library Online

 
vol.64 issue3Effect of anakinra, tocilizumab, and the combination thereof on bladder ischemia- reperfusion damage in albino Wistar-type rats.Aspirin in primary cardiovascular prevention: the two faces of the coin and the importance of the Number Needed to Treat: a systematic review and metaanalysis. author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Investigación Clínica

Print version ISSN 0535-5133On-line version ISSN 2477-9393

Abstract

ARVELO, Francisco  and  SOJO, Felipe. Epithelial-mesenchymal transition and cancer. Invest. clín [online]. 2023, vol.64, n.3, pp.379-404.  Epub Oct 01, 2023. ISSN 0535-5133.  https://doi.org/10.54817/ic.v64n3a10.

Cancer cell migration and invasion are critical components of metastatic disease, the leading cause of death in cancer patients. The epithelium-mesenchyme-transition (EMT) and mesenchyme-epithelium-transition (MET) are pathways involved in cancer metastasis. This process involves the degradation of cell-cell and cell-extracellular matrix junctions and the subsequent loss of regulation of binding proteins such as E-cadherin. Cells undergo a reorganization of the cytoskeleton. These alterations are associated with a change in cell shape from epithelial to mesenchymal morphology. Understanding EMT and MET’s molecular and cellular basis provides fundamental insights into cancer etiology and may lead to new therapeutic strategies. In this review, we discuss some of the regulatory mechanisms and pathological role of epithelial-mesenchymal plasticity, focusing on the knowledge about the complexity and dynamics of this phenomenon in cancer.

Keywords : cancer; epithelium; cadherin; plasticity; epithelial-mesenchymal transition.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )